We teach you about hormonal therapy for breast cancer. Drugs such as tamoxifen and aromatase inhibitors are key treatment options for most breast cancers. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ ________________________________ Questions for your Medical Oncologist: 1. What type of hormonal therapy do you recommend? 2. Will I also benefit from chemotherapy? 3. What are the side effects of hormonal therapy? 4. Will I need 5 or 10 years of these medications? 5. Would the genomic assay Oncotype DX be helpful? 6. What is Hormonal Therapy? Anti-estrogen (estrogen-blocking) medications, prescribed as pills, are incredibly effective at treating certain types of breast cancer. Hormonal therapy is given to about 70 to 80% of women with breast cancer. Chemotherapy, on the other hand, is a more intense cancer treatment that is generally administered intravenously. Most patients will not need chemotherapy. Many women that do need chemotherapy will also benefit from hormonal therapy. These treatment decisions are complex ones with your medical oncologist. You will make better choices when you are well informed before meeting with your medical oncologist. Do my “Receptors” suggest Hormonal Therapy? When the estrogen circulating in your blood stream interacts with a breast cancer that has “Estrogen Receptors” (ER) present on its surface, it tends to flip the ER switch to the “on” or “grow” position for ER Positive tumors. The same can be said to a lesser extent for the “Progesterone Receptor,” if your cancer is found to also be PR positive. Patients with ER+ breast cancers almost always benefit from the anti-estrogen effects of hormonal therapy. These medications can make cancer cells die, or slow down their growth. If a few cancer cells have already spread to other parts of the body, these medications are incredibly effective at preventing these cells from growing and threatening your life in the future. In other words, those who take hormonal therapy for ER+ tumors have a more successful chance at long-term survival when compared to those who do not. About 80% of all breast cancers are ER+. Even if your medical oncologist recommends chemotherapy for you, if your tumor is ER+ you will also benefit from up to 10 years of hormonal therapy after chemotherapy. Hormonal therapy is never given during chemotherapy nor during radiation therapy. What is “Tamoxifen?” Tamoxifen is an anti-estrogen medication (pills) that has been used with great success with ER+ cancers for three decades. It is now the primary hormonal therapy for younger, pre-menopausal women. It is also the primary drug for men with breast cancer. It is used for some post-menopausal women. What are “Aromatase Inhibitors?” Aromatase inhibitors (AIs) are a class of anti-estrogen medications (pills) that have proven to be slightly more effective than Tamoxifen for post-menopausal women. It is not recommended for younger, pre-menopausal women, except in certain circumstances. The three most common versions are Anastrozole (Arimidex), Letrozole (Femara), and Exemestane (Aromasin). What are the side effects of Hormonal Therapy? Side effects vary greatly from one person to the next for both types of hormonal medications. Some have no symptoms at all. Most have very tolerable side effects. Some patients will need to change hormonal therapy medications to find the best balance of cancer benefit versus side effects. Several side effects that are rather common for both tamoxifen and aromatase inhibitors are hot flashes, night sweats, joint pain, and vaginal dryness. Below, we list some of the other specific side effects for both drugs. Tamoxifen Side Effects: Increased risk of uterine (endometrial) cancer Increased risk of developing blood clots Slows normal bone loss in most women (a “good” side effect) Cannot be taken during pregnancy because of risk of birth defects or fetal death Can temporarily induce menopause in pre-menopausal women. Aromatase Inhibitor Side Effects: Can worsen bone loss (osteoporosis) in women Muscle and joint aches and pains Would an “Oncotype DX” assay help me? Patients who have a small, estrogen receptor positive, HER2 receptor negative tumor, and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX genomic assay. This cutting-edge test looks deeper into your cancer cells to better identify people who may also benefit from chemotherapy with ER+ breast cancers. The decision to undergo chemotherapy, in addition to hormonal therapy, is a complicated one. Your medical oncologist uses many factors to help decide if you will benefit from chemotherapy. An Oncotype DX analysis of a portion of your breast cancer tissue can be instrumental in this decision.
Просмотров: 3898 Breast Cancer School for Patients
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ Many women use Anti-Hormone Therapy as a breast cancer treatment but few understand the basics of how it works. Find out as we explain how Hormone Therapy works in simpler terms. To learn more about BCI, go to http://www.breastcanceranswers.com/breastcancerindex/ SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 4596 Breast Cancer Answers®
Dr. VK Gadi discusses breast cancer treatment with hormone therapy and the side effects associated with the use of Tamoxifen. Learn more about breast cancer: http://ow.ly/yC1S3092JIW Subscribe to our channel: http://ow.ly/cw9B308MFsc
Просмотров: 3642 Seattle Cancer Care Alliance
In this show, Dr. James Belanger from the Lexington Natural Health Center will discuss the resistance mechanisms that breast cancer cells use to overcome hormonal therapies such as aromatase inhibitors and Tamoxifen. He will also review the body of research on various natural medicines which may be combined with hormonal therapies to improve their activity and duration of response.
Просмотров: 202 Cancer Concepts & Complements
Dr. thornton gives an overview of the treatment of breast cancer with hormonal agents and chemotherapy.
Просмотров: 49 Ask the Gynecologist
Update from the 2017 San Antonio Breast Cancer Symposium, featuring RISE Advocate Michelle Hille and Dr. Jenny Chang.
Просмотров: 43 Young Survival Coalition
Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Просмотров: 109 OncLiveTV
This cohort study investigates the association between adjuvant tamoxifen and aromatase inhibitor therapy and contralateral breast cancer risk. Read the article at: http://bit.ly/2e5Cql8. Download the video at: http://bit.ly/2dHzn1V.
Просмотров: 182 TheJAMAReport
Antonio Llombart, MD, PhD, of the University Hospital Arnau de Vilanova, Valencia, Spain, discusses new combination treatments for patients with breast cancer at the 2016 World Congress on Controversies in Breast Cancer (CoBrCa) in Barcelona, Spain. He explains that it has been known for almost 40 years that endocrine therapy is the most important treatment for patients with endocrine dependent estrogen receptor-positive early breast cancer. We have been treating these patients with anti-endocrine therapies such as ovarian suppression for more than one century. At some point in the past, the value of ovarian suppression was questioned because it was replaced by endocrine treatments like tamoxifen. However, the question remained whether increasing or adding ovarian suppression to tamoxifen could increase the activity and the prevention for premenopausal patients with endocrine sensitive tumours. Unfortunately for many years, the trials were run with a lot of problems. The main one was that patients also received chemotherapy, which influenced the menopausal status and the trial did not show any benefits. However, in the last 10 years two important trials have been run for premenopausal patients. The trials show that when you combine ovarian suppression with endocrine therapy, the benefits are superior to tamoxifen alone. This, however, does not mean that all patients should receive these combination treatments. It is an option that could be recommended for patients with high risk tumors. Right now the problem we have in early breast cancer premenopausal patients is about deciding the good candidates for this treatment. This is because with this treatment, uncomfortable toxicities are increased. These include a loss of sexual appetite, weight gain and hot flushes, in a way that it can affect quality of life. He ends by explaining that it is a question of balance where it is not just about what is the best treatment but also a negotiation with the patients about what the objectives are.
Просмотров: 43 VJOncology
Say No!! to Aromatase Inhibitors There are two kinds of hormone therapy for breast cancer: 1. One stops estrogen from acting on breast cancer cells, like Tamoxifen. 2. The other interferes with estrogen production by aromatase inhibition (AI), like Letrozole, Anastrozole, and Exemestane. The two therapies differ in their action and side effects (toxicities) 1. The effect of the first is local. It acts only on breast cancer cells and does not interfere with hormone production. 2. Effect the other is systemic. Since interfering with the aromatase enzyme it affects processes in the body which depend on sex hormones. Aromatase inhibitors (AI) have grave side effects. Although Tamoxifen is the best drug on the market it is being replaced by inferior aromatase inhibitors that are far more toxic than tamoxifen. It turns out that AI did not undergo the scrutiny which would justify their distribution. Actually aromatase inhibitors cause a systemic disease, which evolves over time. I shall now explain in plain language how these bad drugs are distributed. These trials were approved by FDA. They represent a trend to replace Overall survival (OS) with Disease free survival (DFS). 1. FDA accepts survival statistics based on two endpoints, clinical and surrogate. 2. Clinical endpoint is always reliable since it is based on a clear cut event, death. 3. Surrogate endpoint is generally unreliable Clinicians who treat these toxicities believe that they are unavoidable. They are regarded as a reasonable price for cancer therapy. In reality these bad drugs are an outcome of a false cancer theory, which is discussed in other presentation.
Просмотров: 10502 Gershom Zajicek M.D,
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, explains the current approach, including some of the challenges, to the management of patients who become pregnant during or after breast cancer.
Просмотров: 91 European Medical Group
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.
Просмотров: 95 OncLiveTV
Frankie Ann Holmes, MD, Texas Oncology, discusses challenges with neoadjuvant endocrine therapy in breast cancer.
Просмотров: 60 Targeted Oncology
2012 Expedition Inspiration Breast Cancer Research Symposium attendee C. Kent Osborne accounts his current breast cancer research
Просмотров: 244 BreastCancerEI
Dr. Eric Winer presented one of the plenary sessions at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. His talk was on endocrine therapy and looking into the future. His prognosis asks the question: Why haven't we done better? And he addresses, what he believes, are the three key issues. Dr. Winer is Chief of Women's Cancers at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.
Просмотров: 1278 Vital Options International
Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.
Просмотров: 53 OncLiveTV
Massimo Cristofanilli, MD, professor of Medcine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endrcrine therapy for patients with breast cancer.
Просмотров: 123 OncLiveTV
A dialogue with Dr. Paul Goss and Dr. Bruce Chabner During this educational session, Dr. Bruce Chabner will host Dr. Paul Goss as they discuss Aromatase Inhibitors and their role in the treatment of breast cancer. Since 80% of breast cancers express hormone receptors, it is no wonder that endocrine therapy plays a crucial role in the treatment of this disease. We are fortunate to have Dr. Goss, a world-class expert in this fast-paced field, give us the status of Aromatase Inhibitors in Breast Cancer Therapy.
Просмотров: 8044 TheOncologistJournal
Panelists Adam M. Brufsky, MD, PhD; Kimberly L. Blackwell, MD; Aditya Bardia, MD, MPH; and Mark E. Robson, MD, discuss the trials that address whether all women with breast cancer should receive extended adjuvant endocrine therapy.
Просмотров: 562 OncLiveTV
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials, called SOFT and TEXT were combined and long-term follow up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries. "This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."
Просмотров: 382 curetoday
Joseph Sparano, MD, associate chairman, Clinical Research, Department of Oncology, Montefiore Medical Center, associate director, Clinical Research, Albert Einstein Cancer Center, discusses the ways in which the role of endocrine therapy has evolved over the years as a treatment for patients with breast cancer. Tamoxifen alone was once routinely given to both pre- and postmenopausal women with breast cancer, typically for a period of 5 years. However, research eventually moved towards the use of aromatase inhibitors as a treatment for postmenopausal women, with a continued use of tamoxifen as a treatment for premenopausal women. In both patient populations, the standard treatment duration was 5 years. In the last couple of years, research has supported the use of ovarian function suppression with aromatase inhibitors to treat premenopausal patients with breast cancer. Moreover, recent data suggests that extended adjuvant therapy with aromatase inhibitors, when given for more than the standard 5 years, may be a significantly more effective treatment for patients.
Просмотров: 169 OncLiveTV
Joanne Mortimer, MD, Director of the Womens Cancers Program at City of Hope Comprehensive Cancer Center, Duarte, California
Просмотров: 4751 Vital Options International
Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.
Просмотров: 150 Targeted Oncology
Dr. Julie Gralow sits down with Selma Schimmel and The Group Room at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) for a four-part interview. This is the first in the four-part interview where she discusses new endocrine therapy for metastatic breast cancer patients. Julie Gralow, MD is a medical oncologist who specializes in treating women with breast cancer. She is the Director, Breast Medical Oncology, Seattle Cancer Care Alliance -- Clinical Research Division, Associate Member, Fred Hutchinson Cancer Research Center -- Professor, Medical Oncology Division, University of Washington School of Medicine
Просмотров: 312 Vital Options International
William J. Gradishar, MD, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the treatment of early stage breast cancer with endocrine therapy and considerations following resistance. More on breast cancer: http://www.onclive.com/specialty/breast-cancer
Просмотров: 326 OncLiveTV
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.
Просмотров: 82 OncLiveTV
Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Просмотров: 138 OncLiveTV
Ruth M. O'Regan, MD, director of Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses resistance to endocrine therapy in patients with metastatic, hormone-receptor positive breast cancer.
Просмотров: 187 OncLiveTV
Prof Michael Gnant speaks with ecancer at SABCS 2017 to discuss the outcomes of a multi-centre phase III randomised trial of 2 or 5 years of anastrozole for post-menopausal breast cancer patients after 5 years of endocrine therapy. He describes the near-identical outcomes of patients in terms of disease free survival and overall survival, and notes the improved treatment adherence and reduced risk of bone fractures in women receiving the shorter course.
Просмотров: 59 ecancer
Pamela Munster, MD, Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined the histone deacetylase (HDAC) inhibitor vorinostat in combination with tamoxifen for patients with hormone therapy-resistant breast cancer. For more information on breast cancer, visit http://www.onclive.com/specialty/breast-cancer
Просмотров: 953 OncLiveTV
Dr. Hope Rugo shares her experience on the recommended treatment approach for ER-positive, HER2-negative breast cancer patients. She comments on what is the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumor. She also provides interesting comments on the use of criteria like tumor grade and size to select the patients for adjuvant chemotherapy as well as the usage of IHC markers such hormone receptors ER-positive, PR and Growth Factor Receptor HER2 to identify patients for chemotherapy. Finally, she speaks about tools such Adjuvant! Online and Predict and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy. _______________________________________________________ Hope Rugo, MD, is the Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Просмотров: 9066 Genomic Health, Inc.
Boughey says an ongoing national clinical trial is looking at patients with ER+ breast cancer and treating them with neoadjuvant endocrine therapy. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 55 Targeted Oncology
This cohort study investigates the association between adjuvant tamoxifen and aromatase inhibitor therapy and contralateral breast cancer risk. Read the article at: http://bit.ly/2e5Cql8.
Просмотров: 90 JAMA Network
Dr. Tony Talebi discusses Estrogen Receptor Positive Breast Cancer with Dr. Lippman. For further discussion please visit http://www.HemOnc101.com Breast cancer is the most common female cancer in the US. Important risk factors for breast cancer are age, gender, reproductive history, hormonal factors, and family history. Although a family history of breast and/or ovarian cancer is common in patients diagnosed with breast cancer, less than ten percent of all breast cancers are associated with genetic mutations. Assay of hormone receptors (estrogen [ER] and progesterone [PR] receptors) is an important component of the pathologic evaluation of breast cancer, for both prognostic and predictive purposes, as patients with hormone receptor-positive tumors benefit from the addition of endocrine treatments. The treatment of early stage breast cancer includes the treatment of locoregional disease with surgery, radiation therapy, or both, and the treatment of systemic disease with one or a combination of chemotherapy, endocrine therapy, or biologic therapy. Here, Dr. Tony Talebi discusses the general concepts of what is estrogen receptor positive breast cancer with world renowned breast cancer expert Dr. Marc Lippman, professor and chairman of the department of medicine at the University of Miami. Dr. Marc Lippman pioneered the use of tamoxifen in estrogen receptor positive breast cancer with his early research while at the National Cancer Institute which revolutionized the treatment of breast cancer. The discussion includes symptoms, diagnosis, staging, genetic implications, surgery, radiation therapy, Oncotype DX testing, hormonal therapy including tamoxifen and aromatase inhibitors and chemotherapy for breast cancer. Dr. Marc Lippman credentials: Certifications American Board of Internal Med-Medical Oncology American Board of Internal Medicine American Bd of Int Med-Endocrinology Diabetes & Metabolism Specialties Hematology/Oncology - Internal Medicine Internal Medicine Roles Interim Deputy Director, Sylvester Comprehensive Cancer Center Professor and Chairman Biography Marc E. Lippman, M.D. was named the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and was named Chairman of the Department of Medicine in May 2007. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan, Ann Arbor, Michigan. From 1988 through 1999 Dr. Lippman was Professor of Medicine and Pharmacology, and Chair, Department of Oncology at Georgetown University in Washington, D.C., and served as Director of the Lombardi Cancer Center at Georgetown University Medical Center. From 1978 through 1990 he was Clinical Professor of Medicine and Pharmacology, Uniformed Services, University of the Health Sciences. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the National Institute of Health. He was a Senior Investigator at the National Cancer Institute of the National Institute of Health. Dr. Lippman completed a Fellowship in Endocrinology at Yale Medical School in New Haven, CT from 1973-1974. In addition, he was Clinical Associate at the National Cancer Institute from 1970-1971 and Clinical Associate at the Laboratory of Biochemistry of the National Cancer Institute of the National Institute of Health. From 1970 to 1988 he served as an Officer and Medical Director of the United States Public Health Service. Dr. Lippman completed his residency on the Osler Medical Service, John Hopkins Hospital, in Baltimore, Maryland from 1968-1970. A native of New York, Dr. Lippman received his Bachelor's Degree from Cornell University, Magna Cum Laude, and medical school degree at Yale Medical School in New Haven, CT where he was elected to AOA. Dr. Lippman is widely known for his research in breast cancer. Throughout his illustrious career he has received numerous awards including Mallinckrodt Award of the Clinical Radioassay Society in 1978; the Commendation Medal USPHS in 1982; Meritorius Service Medal, USPHS in 1987; Clinical Investigator Award, American Federation for Clinical Research in 1985; D.R. Edwards Lecture and Medal, Tenovus Institute, Wales 1985; Plenary Lecturer, British Association of Cancer Research in 1987; Gosse Lecture, Dalhuosie University, Halifax Nova Scotia in 1987; the American Cancer Society.
Просмотров: 2152 Tony Talebi, MD
Blockade of the ER signaling pathway is a common therapeutic strategy in advanced breast cancer, but resistance may occur. Palbociclib appears to be safe in combination with endocrine therapy such as letrozole; does the combination improve outcomes? New research findings are summarized in a short video. Learn more at http://nej.md/1WoeHdF
Просмотров: 9496 NEJMvideo
Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy. More from this conference: http://www.onclive.com/conference-coverage/ibc-2014
Просмотров: 138 OncLiveTV
The Executive Dean's Public Lecture series presents Transforming endocrine therapy for breast and prostate cancer, by Dr Luke Selth and Dr Theresa Hickey. Breast cancer is predicted to become the most commonly diagnosed cancer in women in 2017, with one in every eight women estimated to be diagnosed before their 85th birthday. Prostate cancer diagnosis have decreased over the past five years—yet prostate cancer remains the most commonly diagnosed cancer within men. Breast and prostate cancers arise from abnormal hormone receptor activity. The major treatment is to abolish the offending hormone receptor's activity. For some, this treatment is completely ineffective or their cancer becomes rapidly resistant to treatment. Dr Selth and Dr Hickey discuss how they leverage the similarities of breast and prostate cancer to make discoveries aimed at revolutionising the treatment of both diseases, by attempting to reprogram the hormone receptors that drive breast and prostate cancer.
Просмотров: 75 Health & Medical Sciences - University of Adelaide
Learn about BCI: http://www.breastcanceranswers.com/breastcancerindex/ A viewer was concerned about losing more estrogen from anti-hormone therapy. She asked us, "Should I get off of Anti-Estrogen Therapy?" Find out what Medical Director Dr. Jay Harness had to say about it. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 1626 Breast Cancer Answers®